Semaglutide causes significant weight loss. In the largest clinical trial, people taking the 2.4 mg weekly injection lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in those receiving a placebo. That translates to roughly 15.3 kg (about 34 pounds) of actual weight lost. It’s one of the most effective medications available for weight management, and it’s now FDA-approved not only for weight loss but also to reduce the risk of heart attack, stroke, and cardiovascular death in adults with obesity or overweight.
How Semaglutide Causes Weight Loss
Semaglutide mimics a hormone your body already makes called GLP-1, which plays a role in appetite, digestion, and blood sugar regulation. The drug is 94% structurally identical to the natural version, but it’s engineered to last much longer in your body, which is why a single weekly injection works.
It drives weight loss through several overlapping pathways. First, it slows gastric emptying, meaning food stays in your stomach longer and you feel full sooner during meals. Second, it acts on appetite centers in the brain, specifically the hypothalamus, to reduce hunger, curb food cravings, and increase feelings of satisfaction after eating. The combined effect is that people simply eat less without the constant feeling of deprivation that sinks most diets. It also improves blood sugar control by boosting insulin release after meals and suppressing glucagon, a hormone that raises blood sugar.
How Much Weight People Actually Lose
The landmark STEP 1 trial, published in the New England Journal of Medicine, tested weekly 2.4 mg semaglutide injections in adults with obesity or overweight (with at least one weight-related health condition). After 68 weeks, the semaglutide group lost an average of 15.3 kg, while the placebo group lost 2.6 kg. That’s a difference of about 12.7 kg (28 pounds) attributable to the drug itself, since both groups also followed a reduced-calorie diet and increased physical activity.
In a head-to-head trial against liraglutide, an older daily injection in the same drug class, semaglutide produced roughly 2.5 times more weight loss. People on semaglutide lost 15.8% of their body weight, while those on liraglutide lost 6.4%. This made semaglutide the clear leader among injectable weight loss medications at the time of that study.
What the Dose Schedule Looks Like
You don’t start at the full dose. The standard approach begins at 0.25 mg per week, with your dose increasing every four weeks. This gradual ramp-up helps your body adjust and reduces the severity of side effects. It typically takes about 16 to 20 weeks to reach the maintenance dose of 2.4 mg per week. The injection is given once weekly, on the same day each week, under the skin of the abdomen, thigh, or upper arm.
Common Side Effects
Gastrointestinal issues are the most frequent side effects, and they’re common enough that you should expect at least some of them, particularly during the dose increases. In pooled clinical trial data, about 44% of people on semaglutide experienced nausea (compared to 16% on placebo), 30% had diarrhea, 25% had vomiting, and 24% had constipation. For most people, these symptoms are mild to moderate and tend to ease as the body adjusts over several weeks.
The gradual dose escalation exists specifically to manage these effects. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help. A small percentage of people in trials discontinued treatment because of gastrointestinal symptoms, but the majority were able to continue.
Serious Risks to Know About
Semaglutide carries an FDA boxed warning, the most prominent safety label, for thyroid tumors. This is based on animal studies showing a risk of thyroid C-cell tumors in rodents. In human data, the picture is more reassuring: across trials involving tens of thousands of patients, the incidence of thyroid cancer was less than 1%, and reported cases were isolated. A large review covering nearly 70,000 patients across 26 trials found only 86 cases of thyroid cancer total, split relatively evenly between the drug and comparison groups. Still, semaglutide is not appropriate for anyone with a personal or family history of medullary thyroid cancer or a rare condition called multiple endocrine neoplasia syndrome type 2.
Pancreatitis and acute kidney injury have also been reported, but at very low rates. In one large analysis, pancreatitis occurred in 0.07% of semaglutide-treated patients and acute kidney injury in 0.20%.
Weight Regain After Stopping
This is the part many people don’t hear about upfront. Semaglutide works as long as you take it, and stopping it leads to substantial weight regain. In follow-up data from the STEP trials, people who discontinued semaglutide after 68 weeks regained roughly two-thirds of the weight they had lost over the following year. The average treatment loss was 17.3%, but much of that reversed once the drug was no longer suppressing appetite and slowing digestion.
This pattern is consistent across the drug class and reflects the fact that obesity involves persistent biological changes in hunger signaling and metabolism. Semaglutide manages those signals but doesn’t permanently reset them. For most people, effective weight maintenance means staying on the medication long-term, which has significant cost implications.
Cost and Access
The brand-name version for weight loss, Wegovy, has a list price that can run over $1,000 per month without insurance. Novo Nordisk, the manufacturer, offers savings programs for eligible patients. With their current offer, some patients pay as little as $25 per month (with a maximum savings of $100 per month). Self-pay patients can access certain doses for $149 per month through the manufacturer’s program. Insurance coverage varies widely. Some plans cover Wegovy for weight management, others don’t, and prior authorization requirements are common.
Wegovy is approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s also approved for children aged 12 and older with obesity. A separate brand, Ozempic, uses the same drug at lower doses and is approved only for type 2 diabetes, though it’s frequently prescribed off-label for weight loss.
Who Should Not Take It
Beyond the thyroid cancer concern, semaglutide is not recommended for people with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy that’s worsening. It should not be combined with other GLP-1 receptor agonists or used alongside insulin without careful medical supervision. Pregnant or breastfeeding individuals should not use it, and the drug should be stopped at least two months before a planned pregnancy due to its long duration of action in the body.